Press Releases :: BiomX, Inc. (PHGE)

Sep 11, 2022 7:22am EDT

BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 10, 2022 6:30am EDT

BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 07, 2022 3:17am EDT

BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

Aug 04, 2022 11:20am EDT

BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

Jul 06, 2022 1:45am EDT

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

Jun 28, 2022 6:30am EDT

Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

Jun 27, 2022 6:30am EDT

BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

May 24, 2022 1:52am EDT

BiomX Announces Corporate Restructuring

May 20, 2022 8:00am EDT

BiomX Announces Publication in the Journal, Bioinformatics

May 11, 2022 6:30am EDT

BiomX Reports First Quarter 2022 Financial Results and Provides Business Update

1
2
3
4
5
6
7
8
Next

Investor Contact Information

Company

BiomX, Inc.
22 Einstein St.
Floor 5
Ness Ziona 7414003
Israel
info@biomx.com

Investor Relations

Anat Primovich
Corporate Project Manager
T: +972506977228
anatp@biomx.com